Studies That Led to FDA Approval of Axumin as Prostate Cancer Imaging Agent Presented at SNMMI 2016

Studies That Led to FDA Approval of Axumin as Prostate Cancer Imaging Agent Presented at SNMMI 2016
Blue Earth Diagnostics Inc. of Burlington, Massachusetts, announced that it is presenting results from studies that led to the recent U.S. Food and Drug Administration (FDA) approval of its molecular imaging agent Axumin (fluciclovine F 18) to identify prostate cancer recurrence. The presentations are taking place at the Society of Nuclear Medicine and Molecular Imaging meeting now underway in California.

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *